High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis (Q44525952)

3 December 2017

title

High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis (English)

1 reference

peripheral T-cell lymphoma

3 December 2017

main subject

1 reference

Lin Gui

1 reference

3 December 2017

Yuan-kai Shi

1 reference

3 December 2017

Xiao-hui He

1 reference

3 December 2017

Ying-heng Lei

1 reference

3 December 2017

Hong-zhi Zhang

1 reference

3 December 2017

Xiao-hong Han

1 reference

3 December 2017

Sheng-yu Zhou

1 reference

3 December 2017

Peng Liu

1 reference

3 December 2017

Jiang-liang Yang

1 reference

3 December 2017

Mei Dong

1 reference

3 December 2017

Chang-gong Zhang

1 reference

3 December 2017

Sheng Yang

1 reference

3 December 2017

Yan Qin

1 reference

3 December 2017

publication date

21 November 2013

1 reference

International Journal of Hematology

3 December 2017

published in

1 reference

3 December 2017

1 reference

3 December 2017

1 reference

3 December 2017

page(s)

69-78

1 reference

International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-Ameri

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Clinical relevance of immunophenotype in a retrospective comparative study of 297 peripheral T-cell lymphomas, unspecified, and 496 diffuse large B-cell lymphomas: experience of the Intergruppo Italiano Linformi.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

The adjusted International Prognostic Index and beta-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Autologous transplantation for relapsed or primary refractory peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Long-term follow-up of patients with peripheral T-cell lymphomas treated up-front with high-dose chemotherapy followed by autologous stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Frontline autologous stem cell transplantation in high-risk peripheral T-cell lymphoma: a prospective study from The Gel-Tamo Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Intensive chemotherapy (high-dose CHOP/ESHAP regimen) followed by autologous stem-cell transplantation in previously untreated patients with peripheral T-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Autologous stem-cell transplantation as first-line therapy in peripheral T-cell lymphomas: results of a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Long-term results of autologous hematopoietic cell transplantation for peripheral T cell lymphoma: the Stanford experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Peripheral T Cell Lymphoma (PTCL): Analysis of Prognostic Factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of periphera

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Autologous stem cell transplantation in adult patients with peripheral T-cell lymphoma: a nation-wide survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Autologous hematopoietic stem cell transplantation in peripheral T-cell lymphoma using a uniform high-dose regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

CHOP plus etoposide and gemcitabine (CHOP-EG) as front-line chemotherapy for patients with peripheral T cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1465-Y

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

21 January 2018

1 reference

12 December 2020

Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study

1 reference

12 December 2020

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting

1 reference

12 December 2020

Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA).

1 reference

12 December 2020

Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project

1 reference

12 December 2020

Alemtuzumab plus CHOP as front-line chemotherapy for patients with peripheral T-cell lymphomas: a phase II study

1 reference

12 December 2020

Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant

1 reference

12 December 2020

Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study

1 reference

12 December 2020

High-dose therapy and autologous stem-cell transplantation in angioimmunoblastic lymphoma: complete remission at transplantation is the major determinant of Outcome-Lymphoma Working Party of the European Group for Blood and Marrow Transplantation

1 reference

12 December 2020

10.1007/S12185-013-1465-Y

Identifiers

DOI

1 reference

3 December 2017

1 reference